Clovis Oncology Announces $170M Offering of Common Stock
Clovis Oncology (NASDAQ: CLVS) announced today that it has commenced an
underwritten public offering of shares of its common stock to raise
aggregate proceeds of $170 million. All shares of the common stock to be
sold in the offering will be offered by Clovis Oncology.
Clovis Oncology intends to use the net proceeds of the offering for
general corporate purposes, including funding of its development
programs, general and administrative expenses, acquisition or licensing
of additional product candidates or businesses and working capital.
J. P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC are
acting as joint book-running managers for the offering, and Leerink
Swann LLC is acting as co-manager for the offering. In